SLS - NASDAQ
SELLAS Life Sciences Group, Inc.
$8.19
-1.7%SELLAS Life Sciences Group, Inc., a late-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. Its lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase III clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. The company also develops nelipepimut-S, a cancer immunotherapy that targets human epidermal growth factor receptor 2, which is in Phase 2b clinical trials for the treatment of early-stage breast cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors. The company was founded in 2012 and is headquartered in New York, New York.
At a Glance
Live SnapshotSELLAS Life Sciences Group, Inc. Management Team
Dr. Angelos M. Stergiou M.D., ScD h.c.
Founder, President, Chief Executive Officer & Director
Compensation
$994,385
Dr. Dragan Cicic M.D., MBA
Senior Vice President & Chief Development Officer
Compensation
$659,364
Mr. John Thomas Burns CPA
Senior Vice President & Chief Financial Officer
Compensation
$620,894
Mr. Andrew Elnatan
Senior Vice President of Regulatory Affairs, CMC & Quality
Ms. Stacy E. Yeung
Vice President of Legal Affairs, Head of Compliance & Corporate Secretary
SELLAS Life Sciences Group, Inc. Insider Positioning
During the last 12 months, insiders have purchased $116K worth of SLS shares, with no selling activity reported.
3 Months
0
0.00
0
0.00
+0
+$0
3-6 Months
0
0.00
0
0.00
+0
+$0
6-9 Months
63.4K
100.81K
0
0.00
+101K
+$101K
9-12 Months
10.0K
14.80K
0
0.00
+15K
+$15K
Top Buyers
Kalin Katherine Bach
Director
$101K
Van Nostrand Robert L
Director
$15K
Top Sellers
No selling activity
Insider Activity Analysis
Net Insider Sentiment
Strong bullish signal with $116K net buying. Insiders are aggressively accumulating shares, suggesting significant confidence in future prospects.
Buy/Sell Ratio
Perfect buy/sell ratio. Only buying activity with zero selling—the most bullish possible insider signal.
Insider Participation
2 insider buyers vs. 0 sellers. Broad-based buying across management team suggests widespread confidence.
Insider Activity Insight
Compelling insider conviction: The combination of strong buy/sell ratio and multiple buyers suggests insiders see attractive risk/reward. Consider this alongside fundamental analysis for confirmation.
SEC Filings
SLS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
DEF 14A DEF 14A 2026 N/A | April 23, 2026 | June 16, 2026 | 2026 | |
DEF 14A DEF 14A 2025 N/A | April 23, 2025 | June 17, 2025 | 2025 | |
DEF 14A DEF 14A 2024 N/A | April 29, 2024 | June 20, 2024 | 2024 | |
DEF 14A DEF 14A 2023 N/A | April 28, 2023 | June 20, 2023 | 2023 | |
DEF 14A DEF 14A 2022 N/A | April 25, 2022 | June 08, 2022 | 2022 | |
DEF 14A DEF 14A 2021 N/A | April 23, 2021 | June 08, 2021 | 2021 | |
DEF 14A DEF 14A 2020 N/A | April 23, 2020 | June 09, 2020 | 2020 | |
DEF 14A DEF 14A 2019 N/A | August 05, 2019 | September 10, 2019 | 2019 | |
DEF 14A DEF 14A 2019 N/A | May 24, 2019 | July 12, 2019 | 2019 | |
DEF 14A DEF 14A 2018 N/A | April 30, 2018 | June 12, 2018 | 2018 |
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.